

1 **Title:** Differentiation of SARS-CoV-2 naturally infected and vaccinated individuals in an inner-
2 city emergency department

3 **Running Title (36/40):** SARS-CoV-2 infection and vaccination

4 **Authors:**

5 Evan J Beck*¹, Yu-Hsiang Hsieh*², Reinaldo E Fernandez³, Gaby Dashler², Emily R Egbert⁵,
6 Shawn A Truelove⁷, Caroline Garliss³, Richard Wang², Evan M. Bloch⁴, Ruchee Shrestha⁴, Joel
7 Blankson³, Andrea L. Cox³, Yukari C Manabe³, Thomas Kickler⁴, Richard E Rothman², Andrew
8 D Redd^{1,3}, Aaron AR Tobian⁴, Aaron M Milstone^{5,6}, Thomas C Quinn^{1,3,6}, Oliver
9 Laeyendecker^{#1,3,6}

10 **Affiliations:**

11 1) Division of Intramural Research, National Institute of Allergy and Infectious Diseases,
12 National Institutes of Health, Bethesda, Maryland
13 2) Department of Emergency Medicine, Johns Hopkins University School of Medicine,
14 Baltimore, Maryland
15 3) Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
16 4) Department of Pathology, Johns Hopkins University School of Medicine, Baltimore,
17 Maryland
18 5) Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
19 6) Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
20 Maryland
21 7) Department of International Health, Johns Hopkins Bloomberg School of Public Health,
22 Baltimore, Maryland

23

24

25 * These authors contributed equally to this manuscript

26

27 # Corresponding author:

28 Oliver Laeyendecker, PhD,

29 National Institute of Allergy and Infectious Diseases, National Institutes of Health,

30 855 North Wolfe Street, Rangos Building, Room 538A, Baltimore, MD 21205, USA;

31 oleayen1@jhmi.edu

32

33

34 **Summary (40/40):** Using an antibody testing algorithm, we distinguished between immune
35 responses from SARS-CoV-2-infected and vaccinated individuals. When applied to blood
36 samples from an emergency department in Baltimore, disparities in disease burden and vaccine
37 uptake by sex, race, and ethnicity were identified.
38

39 **Key words (up to 5):** Seroprevalence of SARS-CoV-2 antibody; Emergency Department;
40 Factors associated with SARS-CoV-2 infection; COVID-19 vaccination prevalence

41 <u>Author</u>	<u>Email</u>
42 Evan J Beck	ebeck14@jhmi.edu
43 Yu-Hsiang Hsieh	yhiesh1@jhmi.edu
44 Reinaldo E Fernandez	rferna25@jhmi.edu
45 Gaby Dashler	ggladfe1@jhmi.edu
46 Emily Egbert	eegbert1@jh.edu
47 Shawn A Truelove	shawntruelove@jhmi.edu
48 Caroline Garliss	Caroline.Garliss@jhmi.edu
49 Richard Wang	rwang93@jhmi.edu
50 Evan M. Bloch	ebloch2@jhmi.edu
51 Ruchee Shrestha	ruchee@jhu.edu
52 Joel Blankson	jblanks@jhmi.edu
53 Andrea L. Cox	acox6@jhmi.edu
54 Yukari C Manabe	ymanabe@jhmi.edu
55 Thomas Kickler	ttickler@jhmi.edu
56 Richard E Rothman	rrothma1@jhmi.edu
57 Andrew R Redd	aredd2@jhmi.edu
58 Aaron AR Tobian	atobian1@jhmi.edu
59 Aaron Milstone	amilsto1@jhmi.edu
60 Thomas C Quinn	tquinn2@jhmi.edu
61 Oliver Laeyendecker	olaeyen1@jhmi.edu
62	

63 **Abstract (248/250)**

64 **Background:** Emergency Departments (EDs) can serve as surveillance sites for infectious
65 diseases. Our purpose was to determine the burden of SARS-CoV-2 infection and prevalence of
66 vaccination against COVID-19 among patients attending an urban ED in Baltimore City.

67 **Methods:** Using 1914 samples of known exposure status, we developed an algorithm to
68 differentiate previously infected, vaccinated, and unexposed individuals using a combination of
69 antibody assays. We applied this testing algorithm to 4360 samples ED patients obtained in the
70 springs of 2020 and 2021. Using multinomial logistic regression, we determined factors
71 associated with infection and vaccination.

72 **Results:** For the algorithm, sensitivity and specificity for identifying vaccinated individuals was
73 100% and 99%, respectively, and 84% and 100% for naturally infected individuals. Among the
74 ED subjects, seroprevalence to SARS-CoV-2 increased from 2% to 24% between April 2020 and
75 March 2021. Vaccination prevalence rose to 11% by mid-March 2021. Marked differences in
76 burden of disease and vaccination coverage were seen by sex, race, and ethnicity. Hispanic
77 patients, though 7% of the study population, had the highest relative burden of disease (17% of
78 total infections) but similar vaccination rates. Women and White individuals were more likely to
79 be vaccinated than men or Black individuals (adjusted odds ratios [aOR] 1.35 [95% CI: 1.02,
80 1.80] and aOR 2.26 [95% CI: 1.67, 3.07], respectively).

81 **Conclusions:** Individuals previously infected with SARS-CoV-2 can be differentiated from
82 vaccinated individuals using a serologic testing algorithm. SARS-CoV-2 exposure and
83 vaccination uptake frequencies reflect gender, race and ethnic health disparities in this urban
84 context.

85 **Body (2988/3000) & References (38/40)**

86 **Introduction**

87 As of October 2021, over 238 million cases of Severe Acute Respiratory Syndrome
88 Coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19),
89 have been reported globally¹. The United States has recorded more than 700,000 deaths and
90 documented infections in over 10% of the population. Within the U.S., Black and Latino
91 individuals have experienced higher rates of infection and mortality, relative to White
92 individuals, since the onset of the pandemic^{2,3}. Rooted in long-standing racial and structural
93 injustice, these disparate health outcomes reflect the disproportionate effects of social
94 determinants of health among U.S. racial and ethnic minority groups^{4,5}.

95 Currently, three vaccines for COVID-19 have been authorization by the U.S. Food and
96 Drug Administration⁶. The authorized vaccines from Pfizer, Moderna, and Johnson & Johnson,
97 each elicit an immune response against the spike protein of the SARS-CoV-2 virion⁷⁻⁹. As of the
98 20th of September 2021, 74.6% of persons aged ≥ 12 years have received at least one dose of a
99 COVID-19 vaccine in the United States¹⁰. This uptake, however, has varied dramatically by race,
100 socioeconomic status, and geographic location. Several studies have described the potential for
101 vaccine hesitancy among Black and Hispanic Americans¹¹⁻¹³. These issues related vaccine
102 hesitancy and access could result in disparate rates of vaccine uptake among racial and ethnic
103 minority groups.

104 In contrast to vaccinated individuals, naturally infected patients create antibodies to
105 several parts of the virus, including the spike and nucleocapsid proteins¹⁴. By comparing the
106 results of serologic assays that either detect antibodies to spike (S1), the spike glycoprotein

107 receptor binding domain (RBD), or the nucleocapsid (N), it should be possible to distinguish
108 between SARS-CoV-2 naturally infected (either infected alone or infected then vaccinated),
109 vaccinated (with no evidence of prior infection), and uninfected individuals.

110 By providing data on symptomatic infection rates, emergency departments (EDs) have
111 historically played a critical role in prior epidemics and pandemics and thus present a rich
112 opportunity for conducting SARS-CoV-2 serosurveillance¹⁵⁻¹⁷. Although case-reporting can
113 provide an estimate of population-level seroprevalence, relying on case-reporting alone may
114 underestimate the burden of infection, emphasizing the need for accurate serologic assessment of
115 seroprevalence¹⁸.

116

117 **Methods**

118 Ethics Statement:

119 This study used samples from parent studies approved by The Johns Hopkins University School
120 of Medicine Institutional Review Board (IRB00245545, IRB00247886, IRB00091667,
121 IRB00250798, IRB00249350, and NA_00085477). The Moderna vaccine trial was part of the
122 Division of Microbiology and Infectious Diseases Protocol Number: 20-0003. For those studies,
123 all individuals provided written informed consent. The JHU School of Medicine Institutional
124 Review Board (IRB00083646, CIR00016268) approved the de-identified serosurvey performed
125 on waste material. All studies were conducted according to the ethics standards of the Helsinki
126 Declaration of the World Medical Association.

127 Samples for Algorithm Validation

128 Three sample sets with known previous infection and vaccination to SAR-CoV-2 were used to
129 validate the antibody testing algorithm (**Table 1**). Samples with known vaccination were drawn
130 from a phase I trial⁸ (n=68) and vaccinated health care professionals (HCP, n=360)^{20,21}. The 494
131 samples from individuals known to have been infected by SARS-CoV-2 were drawn from three
132 cohorts: convalescent plasma donors (CCP, n=244)^{18,22}; and Clinical Characterization Protocol
133 for Severe Infectious Diseases (CCPSEI, n=246)²³, and HCP (n=4)²⁴. All samples were from
134 individuals with a known positive SARS-CoV-2 RT-PCR test result. The majority of the CCP
135 donors had mild disease, with 9% of this cohort reporting hospitalization. Among the CCPSEI,
136 14% received oxygen therapy, 33% received ventilation, and 13% died. All HCP had mild
137 disease. Additionally, there were 46 HCP who were infected and subsequently vaccinated, 28
138 with confirmed a PCR date and 18 who were suspected as having prior infection (PCR negative,
139 but symptomology indicative of an infection). Specificity of the testing algorithm was then
140 assessed using 992 samples from pre-pandemic remnant CBC samples collected from Johns
141 Hopkins Hospital Emergency Department (JHH ED) patients collected between December 2015
142 and January 2016²⁵.

143 Samples for Algorithm Application

144 The testing algorithm was subsequently applied to two serosurveys conducted among
145 patients attending the JHH ED from 16 March to 30 April 2020 and from 11 January to 10
146 March 2021. As previously described in an identity-unlinked seroprevalence study²⁶, remnant
147 CBC blood samples from ED patients aged >17 years were collected during the study period.
148 Each sample was assigned a unique study code, processed, and stored at -80°C. Basic patient
149 demographic characteristics (age, sex, race, and ethnicity) were abstracted from the ED
150 administrative database, and all identifiers and protected health information removed from the

151 dataset. Data regarding COVID-19 vaccination status was not available. Laboratory testing was
152 then performed on stored specimens after delinking the demographic dataset. Using the unique
153 study code, SARS-CoV-2 serostatus and demographic data were then merged.

154 Laboratory Methods:

155 The testing algorithm required three serologic assays that could differentiate serologic reactivity
156 to SARS-CoV-2 S1, RBD and nucleocapsid. These assays were limited to standard ELISA and
157 point of care assays, as we did not have access to chemiluminescent detection equipment. We
158 selected ELISA based technologies for the initial high throughput screening, thought
159 confirmation testing could include point of care assays. Additional information on the assays
160 used is available in **Supplemental Table 1**.

161 Plasma and serum samples were analyzed using three commercially available serologic
162 assays: the Euroimmun Anti-SARS-CoV-2 ELISA (Mountain Lakes, NJ), the CoronaCHEK™
163 COVID-19 IgG/IgM Rapid Test Cassette (Hangzhou Biotest Biotech Co Ltd), and the Bio-Rad
164 Platelia SARS-CoV-2 Total Antibody ELISA (Marnes-la-Coquette, France). Each assay was
165 selected for previously determined performance^{27,28}, ease-of-use characteristics (standard ELISA
166 technology, no large pieces of equipment necessary) and availability. The Euroimmun ELISA
167 measures IgG responses to the S1 protein of SARS-CoV-2, whereas the Bio-Rad ELISA
168 measures total antibodies to nucleocapsid. Both ELISA assays generate a ratio of the optical
169 density of the sample divided by the control (referred to as a signal to cut-off ratio [S/C]). For the
170 Euroimmun and Bio-Rad ELISAs, an $S/C \geq 0.8$ was considered a positive result. The
171 CoronaCHEK™ lateral flow assay (LFA) tests for the presence of both IgM and IgG antibodies
172 to the receptor-binding domain (RBD) of the spike protein. Any visual band was considered a
173 positive result. Each assay was performed according to the manufacturer's instructions.

174 An algorithm composed of the Euroimmun, Bio-Rad, and CoronaCHEK assays was used
175 to differentiate samples into three groups: naturally infected (who may or may not subsequently
176 be vaccinated); vaccinated (who were never infected); and unexposed (**Figure 1**). All samples
177 were first tested using the Euroimmun ELISA (S1). Next, all positive and indeterminate samples
178 were subsequently tested on CoronaCHEK (RBD). Samples that tested positive on Euroimmun
179 and negative on CoronaCHEK were assumed to be false positives and classified as not naturally
180 infected or vaccinated (unexposed). Samples that tested positive on CoronaCHEK were then
181 tested with the Bio-Rad Total Ab assay (N). Samples which were reactive by Euroimmun and
182 CoronaCHEK but negative for Bio-Rad were considered vaccinated. Those samples with a
183 positive or indeterminate result on Bio-Rad were considered natural infections.

184 Statistical methods:

185 To evaluate the diagnostic accuracy of the testing algorithm for a particular state (vaccinated or
186 naturally infected), the sensitivity for each state was determined from samples with that known
187 status (the training sample sets; **Table 1**). Calculation of specificity included all samples from
188 unexposed individuals and the samples from individuals of the other state. Since sample
189 collection had occurred prior to the availability of the COVID-19 vaccines, both naturally
190 infected and pre-pandemic samples were considered negative samples to calculate the sensitivity
191 and specificity of the algorithm for the detection of vaccinated samples. To calculate algorithm
192 sensitivity and specificity for naturally infected samples, samples from the vaccinated (known to
193 be uninfected) and pre-pandemic cohorts were considered negative samples. The 48 samples
194 from individuals known or suspected to be infected and subsequently vaccinated were not
195 include in determining the performance of the algorithm. Statistically significant differences in
196 the ELISA S/C values between vaccinated and naturally infected individuals were determined

197 using a t-test. Chi-squared and Fisher's exact tests was used to examine the differences in
198 population demographics between the 2020 and 2021 serosurveys. For the JHH ED serosurvey
199 sample sets, factors associated with natural infection or vaccination were assessed with logistic
200 regression. Logistic regression was used to generate odds ratios to compare the odds of natural
201 infection and vaccination in the post-vaccine era with respect to age, sex, and race in the post-
202 vaccine era (spring 2021). A p-value <0.05 was considered significant. Statistical analyses were
203 performed using StataSE version 14.2 (StataCorp, College Station, TX) and SAS version 9.4
204 (SAS Institute., Cary, NC).

205 **Results**

206 Samples from vaccinated individuals without prior SARS-CoV-2 infection (n=428),
207 unvaccinated individuals with PCR confirmed natural infection (n=494), and those seen in the
208 ED pre-pandemic (n=992) were tested on all three assays (**Supplemental Figure 1a**). The
209 Euroimmun S1 ELISA was positive for 100% (95% confidence interval [CI], 99.1-100.0%), 89%
210 (95% CI, 86.2-91.9%), and 3.2% (95% CI, 2.2-4.5%) for vaccinated, naturally infected and pre-
211 pandemic samples, respectively. Similarly, for the Bio-Rad N ELISA, 0% (95% CI, 0.0-0.7%),
212 91% (95% CI, 88.2-93.5%), and 1.4% (95% CI, 0.7-2.4%) were positive for vaccinated,
213 naturally infected and pre-pandemic sample sets. For the CoronaCHEK RBD assay, 100% (95%
214 CI, 99.1-100.0%), 91% (95% CI, 87.8-93.1%), and 0.5% (95% CI, 0.2-1.2%) had any reactive
215 band for vaccinated, naturally infected and pre-pandemic samples. For vaccinated samples,
216 algorithm sensitivity and specificity were 100% (95% CI, 99.1-100.0%) and 98.9% (95 CI, 98.2-
217 99.3%), respectively (**Supplemental Figure 1b**). For naturally infected samples, algorithm
218 sensitivity and specificity were 84.4% (95% CI, 80.9-87.5%) and 100% (95% CI, 99.7-100.0%),
219 respectively (**Supplemental Figure 1c**).

220 There were significant differences between SARS-CoV-2 serostatus and the level of
221 antibody reactivity to spike and nucleocapsid among the cohorts used for algorithm validation
222 (**Figure 2**). For vaccinated individuals, the median S/C value for antibody reactivity against
223 spike was 8.9 (IQR=1.2) compared to 5.2 (IQR=5.3) for infected persons ($p<0.001$). Among the
224 vaccinated persons without previous infection, no individuals had an S/C value for antibody
225 reactivity against nucleocapsid greater than 0.8, the threshold for a positive result, whereas
226 naturally infected patients with no history of vaccination had a median S/C of 4.3 (IQR=0.53)
227 ($p<0.001$). Among HCP, there were 28 samples from individuals with a known SARS-CoV-2
228 PCR positive date who were vaccinated 7 to 103 days later. These individuals had spike antibody
229 S/C values similar to vaccinated individuals (median=9.5, IQR=0.9) and nucleocapsid antibody
230 S/C values similar to naturally infected individuals (median=3.4, IQR=2.9). Additionally, 18
231 HCP who were SARS-CoV-2 PCR negative but had suspected infection, had similar values to
232 those with known infection followed by vaccination, with spike antibody levels (median=10.0,
233 IQR=1.2) and nucleocapsid antibody S/C values (median=3.3 IQR 1.9). Because of the timing
234 of sample collection relative to vaccination, it is very unlikely that these 18 samples represented
235 breakthrough infections. It is more likely that these infections were unconfirmed infections that
236 occurred prior to vaccination. There was little reactivity for samples from pre-pandemic samples.

237 Using the testing algorithm, 1536 JHH ED 2020 samples and 2824 JHH ED 2021
238 samples were evaluated. During the two collection periods, combined seroprevalence of
239 antibodies to SARS-CoV-2 from 1.6% (95% CI, 1.1-2.5%) to 23.8% (95% CI, 22.2-25.4%)
240 (**Figure 3**). During the seven weeks of the second survey, the prevalence of vaccination
241 significantly increased from 2.8% (95% CI, 0.9-6.3%) in mid-January to 11% (95% CI, 8.6-
242 13.7%) by mid-March 2021. The age, sex, and race/ethnic demographics of the two survey

243 periods were similar (**Table 2**). For both surveys, approximately 27% were ≥ 60 years of age,
244 52% female, 60% Black, 26% White and 7% Hispanic. The prevalence of infection in the spring
245 of 2020 did not vary significantly by age, ethnicity, race and sex. In contrast, by the spring of
246 2021, significant differences in infection by age ethnicity, race and sex were observed.

247 The prevalence of antibodies to SARS-CoV-2 indicating previous infection or
248 vaccination is presented in **Table 2**. White women and men had the lowest prevalence of
249 infection both in 2020 and 2021. White women were the only group that had a higher proportion
250 of vaccinated individuals (14%) compared to infected individuals (9%). In the 2021 survey,
251 White women comprised 9% of all infections in 2021, but 27% of all vaccinations. For all other
252 groups, the prevalence of exposure to SARS-CoV-2 was higher than the frequency of
253 vaccination. By the spring of 2021, Hispanic patients had the highest evidence of prior SARS-
254 CoV-2 infection within any ethnic group at 38%.

255 In the 2021 survey, there were no statistically different rates of infection between age
256 groups (Table 3). In contrast, 45- to 59-year-olds were less likely to be vaccinated compared to
257 the youngest individuals (aOR=0.71 (95% CI 0.52, 0.98). Compared to Black women, White
258 women were less likely to be previously infected, aOR 0.46 (95% CI 0.31, 0.67), while Hispanic
259 women and men were three times as likely to be previously infected, aOR 3.11 (95% CI 1.98,
260 4.86) and 2.92 (1.86, 4.58) respectively. When it came vaccination status, White women and
261 men and Hispanic men were all significantly more likely than Black women to have evidence of
262 vaccination, aOR 2.42(95% CI 1.64, 3.56), 1.59 (1.02, 2.47) and 2.04 (95%CI 1.02, 4.08)
263 respectively.

264 We then disaggregated the data by sex, race and ethnicity. In terms of natural infection
265 (**Supplemental Table 2a**), individuals between the ages of 45 to 74 were 22% less likely to have

266 evidence of natural infection than the 18- to 29-year-old JHH ED patients. White individuals
267 were 30% less likely to have been infected compared to Black individuals. Hispanic individuals
268 had more than three times the burden of infection compared to non-Hispanic individuals , aOR
269 3.31 (95% CI 2.16, 5.07). After adjusting for age, and race/ethnicity, women had an increased
270 odds for vaccination compared to men, aOR 1.35 (95% CI: 1.02, 1.80, **Supplemental Table 2b**).
271 In comparison to patients aged 18-29, patients aged 45-59 years less likely to be vaccinated, aOR
272 0.50 (95% CI: 0.31, 0.80). Furthermore, White patients had more than twice the odds of
273 vaccination compared to Black patients, aOR 2.26, 95% CI: 1.67, 3.07) There did not appear to
274 be a significant difference in vaccination with respect to ethnicity, aOR1.25, 95% CI: 0.69, 2.29).

275 **Discussion**

276 This study describes a method for distinguishing between SARS-CoV-2 vaccinated,
277 naturally infected, and uninfected individuals using commercially available serologic assays
278 when no previous vaccination or infection history is available. The algorithm utilized in this
279 study indicates a 10-fold increase in seropositivity to SARS-CoV-2 infection in the Baltimore
280 metropolitan area from April 2020 to March 2021. Furthermore, this study highlights disparities
281 based on sex and race/ethnicity in SARS-CoV-2 prevalence and vaccine distribution within
282 metropolitan Baltimore during the spring of 2021.

283 Our study follows the work of Suhandynata et al.²⁹, in the ability to differentiate
284 vaccinated from infected individuals based on antibody responses to the S1 and N proteins of
285 SARS-CoV-2. In contrast to the Suhandynata et al. study which utilized chemiluminescent
286 assays (Roche Elecsys Anti-SARS-CoV-2 S- and N-antibody)²⁹, we applied more commonly
287 available ELISA and LFA methods in our study. We further expanded their work by
288 incorporating larger validation cohorts and applying the algorithm to population level

289 surveillance. Our study also confirms previous reports of high burden of COVID-19 among the
290 Baltimore Hispanic population³⁰. Additionally, the discrepancies in vaccine uptake among racial
291 and ethnic minority groups are clearly demonstrated. While recent data suggest that racial and
292 ethnic gaps in vaccination have narrowed¹⁰, our data from early 2021 suggests that disparities in
293 vaccination were present in the initial stages of the vaccine rollout. Surprisingly, despite
294 prioritizing older Americans during the vaccine rollout³¹, patients older than 60 were as likely to
295 be vaccinated as those between the ages of 18-44.

296 Our method demonstrated 100% sensitivity in identifying individuals who were fully
297 vaccinated with both the Pfizer and Moderna vaccines. Further studies are needed to determine if
298 other authorized vaccines have similar performance characteristics. One critical potential
299 limitation to the use of anti-spike and anti-nucleocapsid antibody testing to differentiate naturally
300 infected from vaccinated individuals is differential loss of antibody reactivity to these two
301 targets. In a cohort of 3276 UK healthcare workers, Lumley et al. estimated that anti-
302 nucleocapsid IgG antibodies exhibit a half-life of 85 days from the maximum titer (95% CI, 81-
303 90)³². In contrast, the half-life of anti-spike IgG antibodies could not be measured, as 94% of
304 healthcare workers did not exhibit significant loss during follow-up³². Additionally, anti-
305 nucleocapsid antibody decline was more rapid in younger patients and those with milder
306 symptoms. Thus, in the proposed algorithm, a proportion of naturally infected individuals will be
307 misclassified as vaccinated as anti-nucleocapsid antibodies wane with time. This effect will be
308 differential by age and initial symptomology. The time to seroreversion of spike and
309 nucleocapsid antibodies in SARS-CoV-2 infected patients is significantly affected by both
310 disease severity and assay platform. The effect of these variations should be considered when
311 interpreting the results of serosurveillance studies.

312 Our study has several additional limitations. We did not test any individuals with known
313 breakthrough infection (vaccinated then infected), nor could we distinguish between naturally
314 infected individuals who were and were not subsequently vaccinated. Furthermore, a lack of
315 seroreactivity occurred in a minority of naturally infected individuals. The lack of
316 seroconversion in infected individuals has been observed in other studies, and occurs most
317 frequently in individuals with asymptomatic infection³³⁻³⁵. Using our testing algorithm, 16% of
318 individuals with a previous positive RT-PCR test were seronegative by our algorithm. Similarly,
319 Self et al. found that in a convenience sample of 156 mildly infected frontline healthcare
320 personnel, 93.6% experienced a decline in antibody response and 28.2% seroreverted within 60
321 days³⁶. These studies illustrate the difficulty of identifying infected persons several months after
322 infection, especially in cases of mild infection. It should be noted that antibody reactivity is also
323 dependent on the assay used, especially at 6 months after SARS-CoV-2 infection³⁷.

324 Although the correlates of antibody protection for naturally infected individuals have not
325 been well-established³⁸, we demonstrated that a serosurvey can be performed to differentiate
326 vaccinated, naturally infected and at-risk unexposed individuals in a population when
327 vaccination or infection history is not available. This information provides evidence for targeted
328 public health intervention in preparation for the continued spread of endemic SARS-CoV-2
329 infections.

330

331

332 **Funding:** This work was supported by the Division of Intramural Research, National Institute of
333 Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Other support

334 was provided by extramural support from NIAID [R01AI120938, R01AI120938S1, and
335 R01AI128779 to A.A.R.T.; K01AI100681 to Y.-H.H.; UM1-AI068613 for supporting R.E.F.];
336 the NIH Center of Excellence in Influenza Research and Surveillance [HHSN272201400007C to
337 R.E.R.]; and the National Heart Lung and Blood Institute [K23HL151826 to E.M.B.].

338 **Acknowledgements:** The authors would like to acknowledge the staff and patients at the Johns
339 Hopkins Hospital for making this research possible. We thank Morgan Keruly, Ethan Klock and
340 Olivia Ajayi for technical assistance. We would also like to thank the generosity of the collective
341 community of donors to the Johns Hopkins University School of Medicine and the Johns
342 Hopkins Health System for COVID research.

343

344 **References**

- 345 1. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Accessed June 8, 2021.
346 <https://coronavirus.jhu.edu/map.html>
- 347 2. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic
348 Disparities. *JAMA - J Am Med Assoc.* 2020;323(24):2466-2467.
349 doi:10.1001/jama.2020.8598
- 350 3. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case
351 Surveillance — United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep.*
352 2020;69(24):759-765. doi:10.15585/mmwr.mm6924e2
- 353 4. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and
354 Address Racial and Ethnic Disparities. *J Racial Ethn Heal Disparities.* 2020;7(3):398-
355 402. doi:10.1007/s40615-020-00756-0
- 356 5. Yancy CW. COVID-19 and African Americans. *JAMA - J Am Med Assoc.*
357 2020;323(19):1891-1892. doi:10.1001/jama.2020.6548
- 358 6. COVID-19 Vaccines | FDA. Accessed June 8, 2021. [https://www.fda.gov/emergency-
359 preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines)
- 360 7. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based
361 Covid-19 Vaccine Candidates. *N Engl J Med.* 2020;383(25):2439-2450.
362 doi:10.1056/nejmoa2027906
- 363 8. Jackson LA, Anderson EJ, Roupael NG, et al. An mRNA Vaccine against SARS-CoV-2
364 — Preliminary Report. *N Engl J Med.* 2020;383(20):1920-1931.

- 365 doi:10.1056/nejmoa2022483
- 366 9. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
367 Vaccine against Covid-19. *N Engl J Med*. Published online April 21,
368 2021:NEJMoa2101544. doi:10.1056/NEJMoa2101544
- 369 10. CDC COVID Data Tracker. Accessed June 10, 2021. [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic)
370 [tracker/#vaccination-demographic](https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic)
- 371 11. Momplaisir FM, Kuter BJ, Ghadimi F, et al. Racial/Ethnic Differences in COVID-19
372 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic Hospitals. *JAMA*
373 *Netw Open*. 2021;4(8):e2121931-e2121931.
374 doi:10.1001/JAMANETWORKOPEN.2021.21931
- 375 12. Coustasse A, Kimble C, Maxik K. COVID-19 and Vaccine Hesitancy: A Challenge the
376 United States Must Overcome. *J Ambul Care Manage*. 2021;44(1):71-75.
377 doi:10.1097/JAC.0000000000000360
- 378 13. Burger AE, Reither EN, Mamelund SE, Lim S. Black-white disparities in 2009 H1N1
379 vaccination among adults in the United States: A cautionary tale for the COVID-19
380 pandemic. *Vaccine*. 2021;39(6):943-951. doi:10.1016/j.vaccine.2020.12.069
- 381 14. Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to
382 nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in
383 patients with coronavirus disease 2019. *J Infect Dis*. 2020;222(2):206-213.
384 doi:10.1093/infdis/jiaa273
- 385 15. Baker JL, Kelen GD, Sivertson KT, Quinn TC. Unsuspected Human Immunodeficiency

- 386 Virus in Critically Ill Emergency Patients. *JAMA J Am Med Assoc.* 1987;257(19):2609-
387 2611. doi:10.1001/jama.1987.03390190087025
- 388 16. Patel EU, Laeyendecker O, Hsieh YH, Rothman RE, Kelen GD, Quinn TC. Parallel
389 declines in HIV and hepatitis C virus prevalence, but not in herpes simplex virus type 2
390 infection: A 10-year, serial cross-sectional study in an inner-city emergency department. *J*
391 *Clin Virol.* 2016;80:93-97. doi:10.1016/j.jcv.2016.05.003
- 392 17. Sampath R, Russell KL, Massire C, et al. Global surveillance of emerging influenza virus
393 genotypes by mass spectrometry. *PLoS One.* 2007;2(5):489.
394 doi:10.1371/journal.pone.0000489
- 395 18. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially
396 available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals
397 with high neutralizing titers. *J Clin Microbiol.* 2021;59(2). doi:10.1128/JCM.02257-20
- 398 19. Waxman MJ, Moschella P, Duber HC, et al. Emergency department-based COVID-19
399 vaccination: Where do we stand? *Acad Emerg Med.* 2021;28(6).
400 doi:10.1111/ACEM.14261
- 401 20. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine
402 Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care
403 Personnel — 33 U.S. Sites, January–March 2021. *MMWR Morb Mortal Wkly Rep.*
404 2021;70(20):753-758. doi:10.15585/mmwr.mm7020e2
- 405 21. Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN.
406 Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. *J Clin*
407 *Invest.* 2020;130(12):6631-6638. doi:10.1172/JCI143120

- 408 22. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses
409 in a COVID-19 convalescent plasma donor population. *J Clin Invest.* 2020;130(11):6141-
410 6150. doi:10.1172/JCI142004
- 411 23. Blair PW, Brown DM, Jang M, et al. The Clinical Course of COVID-19 in the Outpatient
412 Setting: A Prospective Cohort Study. *Open Forum Infect Dis.* 2021;8(2).
413 doi:10.1093/ofid/ofab007
- 414 24. Egbert E, Xiao S, Colantuoni E, et al. Longitudinal cohort of SARS-CoV-2 natural
415 infection among healthcare workers depicts prolonged antibody durability. *JAMA Netw*
416 *Open.* Published online 2021.
- 417 25. Mohareb AM, Patel A V., Laeyendecker OB, et al. The HIV Screening Cascade: Current
418 Emergency Department-Based Screening Strategies Leave Many Patients With HIV
419 Undiagnosed. *J Acquir Immune Defic Syndr.* 2021;87(1):e167-e169.
420 doi:10.1097/QAI.0000000000002609
- 421 26. Laeyendecker O, Hsieh Y-H, Rothman RE, et al. Demographic and clinical correlates of
422 acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency
423 department. *Am J Emerg Med.* 2021;48:261-268. doi:10.1016/j.ajem.2021.04.081
- 424 27. Patel EU, Bloch EM, Clarke W, et al. Comparative Performance of Five Commercially
425 Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify
426 Individuals with High Neutralizing Titers. *J Clin Microbiol.* 2021;59(2).
427 doi:10.1128/JCM.02257-20
- 428 28. Conklin SE, Martin K, Manabe YC, et al. Evaluation of Serological SARS-CoV-2 Lateral
429 Flow Assays for Rapid Point-of-Care Testing. *J Clin Microbiol.* 2021;59(2).

- 430 doi:10.1128/JCM.02020-20
- 431 29. Suhandynata RT, Bevins NJ, Tran JT, et al. SARS-CoV-2 Serology Status Detected by
432 Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive
433 Immune Responses. *medRxiv Prepr Serv Heal Sci*. Published online March 12,
434 2021:2021.03.10.21253299. doi:10.1101/2021.03.10.21253299
- 435 30. Martinez DA, Hinson JS, Klein EY, et al. SARS-CoV-2 Positivity Rate for Latinos in the
436 Baltimore-Washington, DC Region. *JAMA - J Am Med Assoc*. 2020;324(4):392-395.
437 doi:10.1001/jama.2020.11374
- 438 31. Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine
439 prioritization strategies by age and serostatus. *Science (80-)*. 2021;371(6532):916-921.
440 doi:10.1126/science.abe6959
- 441 32. Lumley SF, Wei J, O'Donnell D, et al. The duration, dynamics and determinants of
442 SARS-CoV-2 antibody responses in individual healthcare workers. *Clin Infect Dis*.
443 Published online January 6, 2021. doi:10.1093/cid/ciab004
- 444 33. Eyre DW, Lumley SF, O'Donnell D, et al. Stringent thresholds in SARS-CoV-2 IgG
445 assays lead to under-detection of mild infections. *BMC Infect Dis*. 2021;21(1).
446 doi:10.1186/s12879-021-05878-2
- 447 34. Harritshøj LH, Gybel-Brask M, Afzal S, et al. Comparison of 16 serological SARS-CoV-2
448 immunoassays in 16 clinical laboratories. *J Clin Microbiol*. 2021;59(5).
449 doi:10.1128/JCM.02596-20
- 450 35. Younes S, Al-Jighefee H, Shurrah F, et al. Diagnostic efficiency of three fully automated

- 451 serology assays and their correlation with a novel surrogate virus neutralization test in
452 symptomatic and asymptomatic SARS-COV-2 individuals. *Microorganisms*. 2021;9(2):1-
453 16. doi:10.3390/microorganisms9020245
- 454 36. Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies
455 After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital
456 Network — 12 States, April–August 2020. *MMWR Surveill Summ*. 2020;69(47):1762-
457 1766. doi:10.15585/mmwr.mm6947a2
- 458 37. Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and
459 detectability are driven by disease severity, timing, and assay. *medRxiv*. Published online
460 March 5, 2021:2021.03.03.21251639. doi:10.1101/2021.03.03.21251639
- 461 38. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
462 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*
463 2021 277. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8

464

465

466 **Table 1:** Description of Cohorts

Cohort Name (IRB number)	Purpose	Number of Samples	Notes
NIH Phase 1 Vaccine Trial (20-0003)	Positive Control – Known SARS- CoV-2 Vaccinated	68	68 vaccinated samples with no prior infection
JHHS Health Care Professionals (IRB00249350)	Positive Control – Known SARS- CoV-2 Vaccinated & some naturally infected	410	360 vaccinated samples with no prior infection 28 vaccinated samples with prior infection 18 vaccinated samples with suspected prior infection 4 unvaccinated sample with prior infection
Potential Convalescent Plasma Donors (IRB00250798)	Positive Control – Known SARS- CoV-2 Infected	244	Known infected (PCR positive) and non-vaccinated
CCPSEI (IRB00247886 and IRB00091667)	Positive Control – Known SARS- CoV-2 Infected	246	Known infected (PCR positive) and non-vaccinated
JHH ED 2016 (NA_00085477)	Pre-Pandemic negative control	992	Pre-pandemic samples from the same survey site as pandemic surveillance site
JHH ED 2020: 16 March to 30 April (IRB00083646, CIR00016268)	Algorithm Application	1536	Population surveillance
JHH ED 2021: 11 January to 10 March (IRB00083646, CIR00016268)	Algorithm Application	2824	Population surveillance

467 Abbreviations: CCPSEI, Clinical Characterization Protocol for Severe Infectious Diseases; ED,
468 emergency department; JHHS, Johns Hopkins Healthcare System; JHH Johns Hopkins Hospital;
469 PCR, polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Syndrome
470 Coronavirus 2.

471 **Table 2:** Demographic Characteristics and Seroprevalence of Infection and Vaccination in Emergency Department Patients in the
 472 Spring of 2020-2021

Characteristics	Category	16 March to 30 April 2020		11 January to 10 March 2021		
		n=1536	Natural Infected n=26 (%)	n=2824	Natural Infected n=444 (%)	Vaccinated n=229 (%)
Age	18-29 years	285	3 (1.1)	578	103 (23.2)	51 (8.8)
	30-44 years	411	2 (0.5)	763	128 (28.8)	70 (9.2)
	45-59 years	434	9 (2.1)	664	100 (22.5)	31 (4.7)
	60-74 years	318	9 (2.8)	599	80 (18.0)	58 (9.7)
	≥ 75 years	87	3 (3.4)	215	32 (14.9)	19 (8.8)
	Missing	1	0 (0.0)	5	1 (20.0)	0 (0.0)
Ethnicity/Race/Sex	NH Black Female	490	4 (0.8)	880	150 (17.0)	55 (6.3)
	NH White Female	201	0 (0.0)	442	38 (8.6)	61 (13.8)
	Hispanic Female	54	2 (3.7)	95	37 (38.9)	8 (8.4)
	Other Female	47	3 (6.4)	108	17 (15.7)	15 (13.9)
	NH Black Male	436	7 (2.3)	738	101 (13.7)	33 (4.4)
	NH White Male	197	3 (1.7)	382	51 (13.4)	37 (9.7)
	Hispanic Male	61	2 (3.3)	96	36 (37.5)	11 (11.5)
	Other Male	50	2 (4.0)	83	14 (16.9)	9 (10.8)

473 Abbreviations: NH non-Hispanic.

474 **Table 3. Factors associated with Antibody Positive to SARS-CoV-2 Among Individuals**
 475 **Attending the JHH ED between 11 January to 10 March 2021.**

Characteristics	Category	OR of Natural Infection (95% CI)	Adj. OR of Natural Infection (95% CI)	OR of Vaccination (95% CI)	Adj. OR of Vaccination (95% CI)
Age	18-29 years	1	1	1	1
	30-44 years	0.93 (0.70, 1.24)	0.86 (0.64, 1.16)	1.04 (0.72, 1.52)	0.99 (0.67, 1.46)
	45-59 years	0.82 (0.61, 1.11)	0.84 (0.62, 1.14)	0.51 (0.32, 0.80)	0.51 (0.32, 0.82)
	60-74 years	0.71 (0.52, 0.98)	0.76 (0.55, 1.06)	1.11 (0.75, 1.64)	1.13 (0.75, 1.69)
	≥ 75 years	0.81 (0.52, 1.24)	0.94 (0.60, 1.46)	1.00 (0.58, 1.74)	0.88 (0.50, 1.55)
	Missing	N.E.	N.E.	N.E.	N.E.
Ethnicity/Race/Sex	NH Black Female	1	1	1	1
	NH White Female	0.46 (0.31, 0.67)	0.46 (0.32, 0.67)	2.40 (1.64, 3.53)	2.42 (1.64, 3.56)
	Hispanic Female	3.11 (1.98, 4.86)	3.08 (1.96, 4.84)	1.38 (0.64, 2.99)	1.36 (0.62, 2.97)
	Other Female	0.91 (0.53, 1.57)	0.92 (0.53, 1.60)	2.42 (1.32, 4.45)	2.47 (1.34, 4.57)
	NH White Male	0.75 (0.53, 1.06)	0.77 (0.55, 1.09)	1.61 (1.04, 2.49)	1.59 (1.02, 2.47)
	NH Black Male	0.77 (0.59, 1.02)	0.79 (0.60, 1.04)	0.70 (0.45, 1.09)	0.72 (0.46, 1.13)
	Hispanic Male	2.92 (1.86, 4.58)	3.01 (1.90, 4.77)	1.94 (0.98, 3.85)	2.04 (1.02, 4.08)
	Other Male	0.99 (0.54, 1.80)	0.99 (0.54, 1.81)	1.82 (0.87, 3.84)	1.87 (0.89, 3.94)

476 Abbreviations: Adj. Adjusted; OR Odds Ratio; CI confidence interval; n, number; NH non-
 477 Hispanic.

478

479

480

481

482

483

484

485

486

487 **Figure Legends:**

488 **Figure 1.** Antibody testing algorithm.

489 An $S/C \geq 0.8$ result on the Euroimmun Anti-SARS-CoV-2 ELISA (S-1) and positive result on
490 the CoronaCHEK™ COVID-19 IgG/IgM Rapid Test Cassette (RBD) were considered positive
491 for the SARS-CoV-2 spike protein. An $S/C \geq 0.8$ result on Bio-Rad Platelia SARS-CoV-2 Total
492 Antibody ELISA (nucleocapsid) was considered a natural infection, whereas an $S/C < 0.8$ in
493 combination with a positive result for spike/RBD indicated vaccination. Samples with negative
494 tests on either Euroimmun or CoronaChek were considered unexposed to either SARS-CoV-2
495 infection or COVID-19 vaccination.

496

497 **Figure 2.** Comparison of ELISA values between vaccinated and naturally infected individuals.

498 Samples with known serostatus from the algorithm validation cohorts were tested on both the
499 Euroimmun Anti-SARS-CoV-2 IgG ELISA (spike) and on Bio-Rad Platelia SARS-CoV-2 Total
500 Antibody ELISA (nucleocapsid). Each ELISA assay generates a ratio of the optical density of
501 the sample divided by a manufacturer-provided calibrator. The y-axis is given as a signal to cut-
502 off ratio (S/C). Medians and interquartile ranges are displayed for each violin plot. The
503 vaccinated group was comprised of individuals with documented vaccination and no previous
504 positive PCR or serological result. SARS-CoV-2 infections were confirmed by a positive PCR
505 result. The vaccination and confirmed infection group was composed of individuals with both
506 documented vaccination and PCR positive infection. Presumed infections were characterized by
507 a lack of PCR positive result, but a positive result for nucleocapsid on the Bio-Rad assay.

508 Samples in the not vaccinated or infected category were obtained from the JHH ED in 2016,
509 prior to the advent of the COVID-19 pandemic.


510

511 **Figure 3.** Seroprevalence of antibodies of SARS-CoV-2 2020-2021.

512 JHHED ED samples from 2020 and 2021 were tested on the previously mentioned algorithm and
513 categorized according to the date on which the sample was drawn.

514

515 **Figure 1.**



516

517


518

519

520


521

522 **Figure 2.**



523
524
525
526
527
528
529

530 **Figure 3.**



531
532

533

534

535

536

537

538 **Supplemental Table 1:** Characteristics of Utilized Commercial SARS-CoV-2 Assays

Manufacturer	Assay Name	Target antigen (recombinant)	Platform	Manufacturer's Interpretation
Euroimmun, Lubeck, Germany	Anti-SARS-CoV-2 ELISA (IgG)	Spike-1 protein	Manual ELISA	Negative: S/C ratio <0.8 Borderline: S/C ratio ≥0.8 & <1.1 Positive: S/C ratio ≥1.1
Hangzhou Biotest Biotech Co. Ltd., Hangzhou, China	CoronaCHEK™ COVID-19 IgG/IgM Rapid Test Cassette	Spike RBD	Lateral Flow Assay	IgG and IgM Positive: Three lines appear IgG Positive: Control and IgG lines appear IgM Positive: Control and IgM lines appear Negative: One line in control region Invalid: No control line
Bio-Rad Laboratories, Inc., Hercules, CA, USA	Platelia SARS-CoV-2 Total Ab assay	Nucleocapsid Protein	Manual ELISA	Negative: S/C ratio < 0.8 Equivocal: S/C ratio ≥ 0.8 & < 1.0 Positive: S/C ratio ≥ 1.0

539 Abbreviations: ELISA, enzyme-linked immunosorbent assay; S/C, signal to control; RBD,
540 receptor binding domain.

541

542

543

544

545 **Supplemental Table 2a: Demographic Characteristics Associated with Natural Infection among**
 546 **2595 Emergency Department Patients, January –March 2021**

547

Characteristics	Category	Crude OR (95% CI)	Adjusted OR (95% CI)
Age	18-29 years	1.00	1.00
	30-44 years	0.93 (0.70, 1.24)	0.86 (0.64, 1.16)
	45-59 years	0.77 (0.57, 1.05)	0.78 (0.57, 1.07)
	60-74 years	0.71 (0.52, 0.98)	0.78 (0.56, 1.08)
	≥ 75 years	0.80 (0.52, 1.24)	0.94 (0.60, 1.46)
Sex	Male	1.00	1.00
	Female	1.06 (0.86, 1.30)	1.04 (0.84, 1.28)
Race	Black	1.00	1.00
	White	0.73 (0.56, 0.94)	0.70 (0.54, 0.91)
	Other	2.25 (1.70, 2.96)	1.24 (0.85, 1.79)
Ethnicity	Non-Hispanic	1.00	1.00
	Hispanic	4.08 (2.96, 5.63)	3.31 (2.16, 5.07)

548 Abbreviations: Adj, Adjusted; CI confidence interval; OR, Odds Ratio; n, number; NH non-
 549 Hispanic.

550

551

552

553 **Supplemental Table 2b: Demographic Characteristics Associated with Evidence of Vaccination**
554 **among 2380 Emergency Department Patients, January –March 2021**
555

Characteristics	Category	Crude OR (95% CI)	Adjusted OR (95% CI)
Age	18-29 years	1.00	1.00
	30-44 years	1.03 (0.70, 1.51)	0.98 (0.67, 1.45)
	45-59 years	0.48 (0.30, 0.77)	0.50 (0.31, 0.80)
	60-74 years	1.05 (0.70, 1.56)	1.09 (0.73, 1.65)
	≥ 75 years	0.96 (0.55, 1.68)	0.86 (0.49, 1.52)
Sex	Male	1.00	1.00
	Female	1.36 (1.03, 1.80)	1.35 (1.02, 1.80)
Race	Black	1.00	1.00
	White	2.30 (1.71, 3.11)	2.26 (1.67, 3.07)
	Other	2.61 (1.73, 3.91)	2.42 (1.51, 3.88)
Ethnicity	Non-Hispanic	1.00	1.00
	Hispanic	1.88 (1.13, 3.13)	1.25 (0.69, 2.29)

556 Abbreviations: Adj, Adjusted; CI confidence interval; OR, Odds Ratio; n, number; NH non-
557 Hispanic.

558

559

560

561

562

563 **Supplemental Figure 1a.** Testing algorithm results on samples from known vaccinated,
564 naturally infected and pre-pandemic samples.

565

566 **Supplemental Figure 1b.** Determination of sensitivity and specificity of vaccinated state in
567 testing algorithm.

568

569 **Supplemental Figure 1c.** Determination of sensitivity and specificity of naturally infected state
570 in testing algorithm.

571

572 **Supplemental Figure 2a.** Testing algorithm results for ED samples collected in 2020.

573

574 **Supplemental Figure 2b.** Testing algorithm results for ED samples collected in 2021.

575


576 **Supplemental Figure 3a.** Euroimmun S/C values of antibody response against spike protein by
577 days post-second dose or confirmed infection. Euroimmun index values were plotted against
578 time since receipt of the second dose of a vaccine (vaccinated samples) or time since confirmed
579 SARS-CoV-2 PCR-positive infection (infected samples and vaccinated/infected samples).

580

581 **Supplemental Figure 3b.** Bio-Rad S/C values of antibody response against nucleocapsid by
582 days post-second dose or confirmed infection. Bio-Rad index values were plotted against time


- 583 since receipt of the second dose of a vaccine (vaccinated samples) or time since confirmed
584 SARS-CoV-2 PCR-positive infection (infected samples and vaccinated/infected samples).

585 **Supplementary Figure 1a.**




598 **Supplementary Figure 1b.**

	Vaccinated	Not vaccinated
Euroimmun / CoronaCHEK positive/ BioRad Negative	428	17
Any other outcome	0	1469



608 **Supplementary Figure 1c.**


	Infected	Not Infected
Euroimmun / CoronaCHEK positive/ BioRad Positive	417	0
Any other outcome	77	1420



612 **Supplementary Figure 2a.**

613


614




615 **Supplementary Figure 2b.**

616


617



618 **Supplementary Figure 3a.**



624 **Supplementary Figure 3b.**



625
626

627